[siRNA in macular degeneration].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
J Callizo, H T Agostini

Abstract

To date aptamers, recombinant antibodies and antibody fragments which interfere specifically in cellular signal transmission by binding transmitters before a signal can be triggered, are the approved therapeutics agents for treatment of ocular angiogenesis. These substances achieve an effective but in most cases temporary inhibition of vascular growth and permeability. Other alternatives to inhibit cellular communication, such as tyrosine kinase inhibition or especially post-transcriptional gene silencing by degradation of messenger RNA (mRNA) induced by small interfering RNA (siRNA) are being evaluated in ongoing studies. In this overview issues related to mechanisms and molecule design, as well as clinical applications and the first clinical experience in ophthalmology reported on siRNA will be discussed.

References

Jul 5, 2002·Nature·Anton P McCaffreyMark A Kay
Apr 14, 2004·Archives of Ophthalmology·David S FriedmanUNKNOWN Eye Diseases Prevalence Research Group
May 14, 2005·Cancer Gene Therapy·Tom C Karagiannis, Assam El-Osta
Jul 26, 2005·Nature Biotechnology·David V MorrisseyBarry Polisky
Jul 13, 2006·Annual Review of Biomedical Engineering·Derek M Dykxhoorn, Judy Lieberman
Jul 29, 2006·Cell·Derek M Dykxhoorn, Judy Lieberman
Mar 28, 2008·Nature·Mark E KleinmanJayakrishna Ambati
May 20, 2008·Journal of Controlled Release : Official Journal of the Controlled Release Society·Sun Hwa KimTae Gwan Park
Aug 30, 2008·The New England Journal of Medicine·Zhenglin YangKang Zhang
Jan 31, 2009·Nature Reviews. Drug Discovery·Kathryn A WhiteheadDaniel G Anderson
Jun 1, 2008·Clinical Ophthalmology·M Vaughn Emerson, Andreas K Lauer

❮ Previous
Next ❯

Citations

Feb 9, 2018·Chemical Society Reviews·Jianliang ShenHaifa Shen

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.